Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.
Research article published in Circulation (2023)
Abstract
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied. METHODS: WATCH-TAVR (WATCHMAN for Patients with AF Undergoing TAVR) was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR + LAAO or TAVR + medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR + medical therapy. The primary noninferiority end point was all-cause mortality, stroke, and major bleeding at 2 years between the 2 strategies. RESULTS: The study enrolled 349 patients (177 TAVR + LAAO and 172 TAVR + medical therapy) between December 2017 and November 2020 at 34 US centers. The mean age of patients was 81 years, and the mean scores for CHA2DS2-VASc and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) were 4.9 and 3.0, respectively. At baseline, 85.4% of patients were taking anticoagulants and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes, and the median contrast volume used for combined procedures was 119 mL versus 70 mL with TAVR alone. At the 24-month follow-up, 82.5% compared with 50.8% of patients were on any antiplatelet therapy, and 13.9% compared with 66.7% of patients were on any anticoagulation therapy in TAVR + LAAO compared with TAVR + medical therapy group, respectively. For the composite primary end point, TAVR + LAAO was noninferior to TAVR + medical therapy (22.7 versus 27.3 events per 100 patient-years for TAVR + LAAO and TAVR + medical therapy, respectively; hazard ratio, 0.86 [95% CI, 0.60-1.22]; Pnoninferiority<0.001). CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03173534.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke.
Por qué esto importa para la hirudoterapia
WATCH-TAVR fue un ensayo clínico multicéntrico aleatorizado (349 pacientes, 34 centros de EE. UU.) que evaluaba si la combinación de la oclusión de la aurícula izquierda (WATCHMAN) con la sustitución valvular aórtica por catéter (TAVR) en pacientes con fibrilación auricular era no inferior a la TAVR más terapia médica; alcanzó su punto final compuesto de no inferioridad de mortalidad, ictus y sangrado mayor a los dos años (razón de riesgos 0,86, IC del 95% 0,60-1,22), con el brazo de oclusión de la LAA reduciendo de manera marcada el uso de anticoagulación a largo plazo, mientras que los autores advertían sobre la complejidad adicional y el riesgo del procedimiento combinado. Para la ASH, el ensayo destaca cuánto esfuerzo clínico se dedica a permitir que los pacientes de alto riesgo eviten la anticoagulación oral de por vida — la misma necesidad del paciente que motiva la investigación sobre antitrombóticos más seguros y específicos de mecanismo, la familia amplia a la que pertenecen los anticoagulantes del secreto de sanguijuelas. Nota honesta: este es un ensayo clínico aleatorizado (RCT) de cardiología de dispositivos y fármacos sin componente de terapia con sanguijuelas; sus hallazgos se aplican a una población específica de fibrilación auricular más estenosis aórtica, y la ASH lo menciona solo como evidencia del impulso clínico para reducir la carga anticoagulante, no como ningún respaldo de la terapia basada en sanguijuelas.
Citación
Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.
Kapadia SR et al. · Circulation, 2023
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026